High tumor expression of TNFRSF14 and CD160, but not TNFSF14, LTA, or BTLA, was associated with improved BLCA patient prognosis, suggesting that the TNFRSF14–CD160 interaction, like KLRK1, is a prominent pathway of NK cell tumor surveillance in BLCA. This evidence concerns the gene CD160 and bladder transitional cell carcinoma.